Linomide Increases Plasma Corticosterone in Normal Rats, but does not Prevent the Inhibitory Action of IL-1 on β-Cells in Vivo or ex Vivo

References

• Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes. 1965; 14: 619–633
   PubMed Web of Science ®Google Scholar
• Mori Y., Suko M., Okudaira H., Matsube I., Tsuruoka A., Sasaki A., et al. Preventive effects of Cyclosporin on diabetes in NOD mice. Diabetologia. 1986; 29: 244–241
   PubMed Web of Science ®Google Scholar
• Brayman K. L., Armstrong J., Shaw L. M., Rosano T. G., Tomaszewski J. E., Barker C. F., et al. Prevention of diabetes in BB rats by intermittent administration of cyclosporine. Surgery. 1987; 102: 235–241
   Google Scholar
• Feutren G., Papoz L., Assan R., Vialette B., Karsenty G., Vexiau P. Cyclosporin increases the rate and length of remissions in insulin‐dependent diabetes of recent onset. Results of a multicentre double‐blinded trial. Lancet. 1986; ii: 119–123
   Google Scholar
• Gross D. J., Sidi H., Weiss L., Kalland T., Rosenmann E., Slavin S. Prevention of diabetes mellitus in non‐obese diabetic mice by Linomide, a novel immunomodulating drug. Diabetologia. 1994; 37: 1195–1201
   PubMed Web of Science ®Google Scholar
• Stålhandske T., Eriskson E., Sandberg B. ‐M. A novel quinolinecarboxamide with interesting immunomodulatory activity. Int. J. Immunopharmacol. 1982; 4: 336
   Web of Science ®Google Scholar
• Tufveson G., Gannedahl G., Johnson C., Olausson M., Wanders A., Ekberg H. New immunosuppressant: testing and development in animal models and the clinic: with special reference to DSG. Immunol. Rev. 1993; 136: 99–109
   Google Scholar
• Kalland T., Alm G., Stålhandske T. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J. Immunol. 1985; 134: 3956–3961
   PubMed Web of Science ®Google Scholar
• Kalland T. Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J. Immunol. 1990; 144: 4472–4416
   PubMed Web of Science ®Google Scholar
• Ilbäck N. ‐G., Fohlman J., Sloarach S., Friman G. Effects of the immunomodulator LS 2616 on lymphocyte subpopulations in murine Coxsackievirus B3 myocarditis. J. Immunol. 1989; 142: 3225–3228
   PubMed Web of Science ®Google Scholar
• Spetz‐Hagberg A. ‐L., Goldschmidt T. J., Stalhandske T., Larson‐Sciard E. ‐L. Amelioration of the intrathymic T cell development and peripheral T cell reactivities in autoimmune mice undergoing therapy with a novel immunomodulator. Int. Immunol. 1990; 2: 645–650
   PubMed Web of Science ®Google Scholar
• Larson E. L., Joki A., Stilhandske T. Mechanisms of action of the new immunomodulator LS 2616 on T‐cell responses. Int. J. Immunopharmacol. 1987; 9: 425–431
   PubMed Web of Science ®Google Scholar
• Kalland T. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16‐F10 melanoma. Cancer Res. 1986; 46: 3018–3022
   PubMed Web of Science ®Google Scholar
• Gonzalo J. A., Gonzáles‐Garacía A., Kalland T., Hedlund G., Martinez A. C., Kroemer G. Linomide, a novel immmunomodulator that prevents death in four models of septic shock. Eur. J. Immunol. 1993; 23: 2372–2374
   PubMed Web of Science ®Google Scholar
• Tarkowski A., Gunnarsson K., Nilsson L. A., Lindholm L., Stålhandske T. Successful treatment of auto‐immunity in MRL/J mice with LS 2616, a new immunomodulator. Arthritis Rheum. 1986; 29: 1405–1409
   PubMed Web of Science ®Google Scholar
• Karussis D. M., Lehmann D., Slavin S., Vourka‐Karussis U., Mizrachi‐Koll R., Ovadia H., et al. Treatment of chronic‐relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator Linomide (quinoline‐3‐carboxamide). Proc. Natl. Acad. Sci. USA. 1993; 90: 6400–6404
   PubMed Web of Science ®Google Scholar
• Karussis D. M., Lehmann D., Slavin S., Kalland T., Vourka‐Karussis U., Mizrachi‐Koll R., Ovadia H., Abramsky O. Immunomodulation of autoimmunity by Linomide. Israel J. Med. Sci. 1995; 31: 38–41
   PubMedGoogle Scholar
• Björk J., Kleinau S. Paradoxical effects of LS‐2616 (Linomide) treatment in type II collagen arthritis model in mice. Agents Actions. 1987; 27: 318–321
   Google Scholar
• Nerup J., Mandrup‐Poulsen T., Helqvist S., Andersen H. U., Pociot F., Reimers J., et al. On the pathogenesis of IDDM. Diabetologia. 1994; 37(suppl. 2)82–89
   PubMedGoogle Scholar
• Mandrup‐Poulsen T., Bendtzen K., Nerup J., Dinarello C. A., Svenson M., Nielsen J. H. Affinity‐purified human interleukin‐1 is cytotoxic to isolated islets of Langerhans. Diabetologia. 1986; 29: 63–67
   PubMed Web of Science ®Google Scholar
• Mandrup‐Poulsen T., Egeberg J., Nerup J., Bendtzen K., Nielsen J. H., Dinarello C. A. Ultrastructural studies of time course and cellular specificity of interleukin‐1‐mediated islet cytotoxcity. Acta. Pathol. Microbiol. Scand. Immunol. Sect. C. 1987; 95: 55–63
   PubMedGoogle Scholar
• Sander S., Bendtzen K., Borg L. A. H., Eizirik D. L., Strandell E., Welsh N. Studies on the mechanisms causing inhibition of insulin secretion in rat pancreatic islets exposed to human interleukin‐1β indicate a pertubation in the mitochondrial function. Endocrinology. 1989; 124: 1492–1501
   Google Scholar
• Jiang Z., Woda B. A. Cytokine gene expression in the islets of the diabetic Biobreeding/Worcester rat. J. Immunol. 1991; 146: 2990–2994
   PubMed Web of Science ®Google Scholar
• Southern C., Schulster D., Green I. C. Inhibition of insulin secretion by interleukin 1β and tumor necrosis factor a via an L‐arginine‐dependent nitric oxide generating mechanism. FEBS Lett. 1990; 276: 42–44
   PubMed Web of Science ®Google Scholar
• Kröncke K. D., Kolb‐Bachofen V., Bershick B., Burkart V., Kolb H. Activated macrophages kill pancreatic syngeneic islet cells via arginine‐dependent nitric oxide generation. Biochem. Biophys. Res. Com. 1991; 175: 752–758
   Google Scholar
• Andersen H. U., Jørgensen K. H., Egeberg J., Mandrup‐Poulsen T., Nerup J. Nicotinamide prevents interleukin‐I effects on accumulated insulin release and nitric oxide production in rat islets of Langerhans. Diabetes. 1994; 43: 770–771
   PubMed Web of Science ®Google Scholar
• Fehsel K., Jalowy A., Qi S., Burkart V., Hartmann B., Kolb H. Islet cell DNA is a target of inflammatory attack by nitric oxide. Diabetes. 1993; 42: 496–500
   PubMed Web of Science ®Google Scholar
• Welsh N., Eizirik D. L., Bendtzen K., Sandier S. Interleukin‐1β induced nitric oxide production in isolated rat pancreatic islets requires gene transcription and may lead to inhibition of the Krebs cycle enzyme aconitase. Endocrinology. 1991; 129: 3167–3173
   PubMed Web of Science ®Google Scholar
• Mølvig J., Sehested Hansen B., Worsaae H., Hejnés K., Helle M., Dalbøge H., Nerup J. Comparison of biological and immunological activities of human monocyte derived interleukin in 1β and human recombinant interleukin 1β. Scand. J. Immunol. 1990; 31: 225–235
   Google Scholar
• Heding L. G. Radioimmunological determination of pancreatic and gut glucagon in plasma. Diabetologia. 1971; 7: 10–19
   PubMed Web of Science ®Google Scholar
• Heding L. G. Determination of total serum insulin (IRI) in insulin‐treated diabetic patients. Diabetologia. 1972; 8: 260–266
   PubMed Web of Science ®Google Scholar
• Brunstedt J., Nielsen J. H., Lernmark Å. the Hage‐dorn Study Group: Isolation of islets from mice and rats. Methods in Diabetes Research, S. L. Larner Johl. Wiley, New York 1984; 1: 254–288
   Google Scholar
• Mandrup‐Poulsen T., Spinas G. A., Prowse S. J., Hansen B. S., Jørgensen D. W., Bendtzen K., Nielsen J. H., Nerup J. Islet cytotoxicity of interleukin 1. Influence of culture conditions and islet donor characteristics. Diabetes. 1987; 36: 641–647
   PubMed Web of Science ®Google Scholar
• Green I. C., Wagner D. A., Glogowski J., Skipper P. L., Wishnok J. S., Tannenbaum S. R. Analysis of nitrate nitrite and ‘15N’nitrate in biological fluids. Anal. Biochem. 1982; 126: 131–138
   PubMed Web of Science ®Google Scholar
• Karussis D. M., Vourka Karussis U., Lemhann D., Ovadia H., Mizrachi‐Koll R., Slavin S., Abramsky O. Inhibition of experimental autoimmune encephalomyelitis with Linomide (LS‐2616), a synthetic immuno‐modulator. Ann. Neurol. 1993; 34: 654–660
   PubMed Web of Science ®Google Scholar
• Björk J., Dawe K., Andersson G., Kalland T., Hedlund G. Development of type 1 diabetes in the NOD mouse is totally inhibited by treatment with Linomide. Autoimmunity. 1995; 21: 6, abst. A022
   Google Scholar
• Yamada K., Takane N., Otabe S., Inada C., Inoue M., Nonaka K. Pancreatic β‐cell‐selective production of tumor necrosis‐alpha induced by interleukin‐1. Diabetes. 1993; 42: 1026–1031
   PubMedGoogle Scholar
• Vukanovic J., Isaacs J. T. Anti‐tumor/antiangiogenic effects of Linomide are not mediated via serum glucocorticoids. Proc. Am. Assoc. Cancer Res. 1993; 84, abst. 381
   Google Scholar
• Mandrup‐Poulsen T., Bendtzen K., Dinarello C. A., Nerup J. Human tumor necrosis factor potentiates human interleukin I‐mediated rat paricreatic β‐cell cytotoxicity. J. Immunol. 1987; 139: 4071–4082
   Google Scholar